Evidence map›Paper›PMID 42506407›Full record

ReviewMetabolites2026

Mangiferin as a Multilevel Modulator of Metabolic Syndrome: Current Evidence and Future Perspectives.

Joan A Ramos-Olvera, J Martín Torres-Valencia, Mario I Ortiz, Eduardo Fernández-Martínez, Carlos A Gómez-Aldapa, Víctor Manuel Muñoz-Pérez, Raquel Cariño-Cortés

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joan A Ramos-OlveraAcademic Area of Medicine, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Eliseo Ramirez Ulloa 400, Doctores, Pachuca 42090, Hidalgo, Mexico.
J Martín Torres-ValenciaAcademic Area of Chemistry, Instituto de Ciencias Básicas e Ingeniería, Universidad Autónoma del Estado de Hidalgo, Km. 4.5 Carretera Pachuca-Tulancingo, Mineral de la Reforma 42184, Hidalgo, Mexico.ORCID 0000-0001-6426-7562
Mario I OrtizAcademic Area of Medicine, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Eliseo Ramirez Ulloa 400, Doctores, Pachuca 42090, Hidalgo, Mexico.
Eduardo Fernández-MartínezAcademic Area of Medicine, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Eliseo Ramirez Ulloa 400, Doctores, Pachuca 42090, Hidalgo, Mexico.ORCID 0000-0003-3280-1323
Carlos A Gómez-AldapaAcademic Area of Chemistry, Instituto de Ciencias Básicas e Ingeniería, Universidad Autónoma del Estado de Hidalgo, Km. 4.5 Carretera Pachuca-Tulancingo, Mineral de la Reforma 42184, Hidalgo, Mexico.ORCID 0000-0002-4723-3093
Víctor Manuel Muñoz-PérezAcademic Area of Medicine, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Eliseo Ramirez Ulloa 400, Doctores, Pachuca 42090, Hidalgo, Mexico.ORCID 0000-0003-1820-0839
Raquel Cariño-CortésAcademic Area of Medicine, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Eliseo Ramirez Ulloa 400, Doctores, Pachuca 42090, Hidalgo, Mexico.ORCID 0000-0003-4776-3534

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

hyperlipidemiahypertensioninsulin resistancemangiferinmetabolic syndromemicrobiotaobesity

Identifiers

PMID42506407
PMCPMC13413803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.